key: cord-0701638-s7pwrlqe
authors: Lee, Jun Young; Shin, Young Sup; Jeon, Sangeun; Lee, Se In; Noh, Soojin; Cho, Jung-Eun; Jang, Min Seong; Kim, Seungtaek; Song, Jong Hwan; Kim, Hyoung Rae; Park, Chul Min
title: Design, Synthesis and Biological Evaluation of 2-Aminoquinazolin-4(3H)-one Derivatives as Potential SARS-CoV-2 and MERS-CoV Treatments
date: 2021-03-02
journal: Bioorg Med Chem Lett
DOI: 10.1016/j.bmcl.2021.127885
sha: def2085720a47c4efe240363963fa933c745523c
doc_id: 701638
cord_uid: s7pwrlqe

Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them. 2-Aminoquinazolin-4(3H)-one derivatives were newly designed, synthesized, and investigated to show the inhibitory effects on SARS-CoV-2 and MERS-CoV. Among the synthesized derivatives, 7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (9g) and 2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one (11e) showed the most potent anti-SARS-CoV-2 activities (IC50 < 0.25 μM) and anti-MERS-CoV activities (IC50 < 1.1 μM) with no cytotoxicity (CC50 > 25 μM). In addition, both compounds showed acceptable results in metabolic stabilities, hERG binding affinities, CYP inhibitions, and preliminary PK studies.

Coronavirus is a single positive-stranded RNA virus that was discovered in 1960 while 27 looking for a new cold virus that infects the upper respiratory tract. 1-2 The clinical significance 28 was relatively low because of its weak symptoms. 3 In the case of COVID-19, Remdesivir, which received urgent approval, as well as Nafamostat, 44 and Hydroxychloroquine, are considered as promising therapeutic candidates. 14 However, due 45 to side effects and low clinical effects, 15 safer and more effective treatments need to be 46 developed.

Our research for novel antivirals inhibiting these fatal coronaviruses started with a 48 biochemical high content screening (HCS) of a library containing 200,000 compounds from 49 Korea Chemical Bank. 16 In the past few years, we reported inhibitors of MERS-CoV such as 50 2-phenylchroman-4-one derivatives, 17 3-acyl-2-phenylamino-1,4-dihydroquinolin-4-(1H)-one 51 derivatives, 18 and 4-aniline-6-amino-quinazoline derivatives 19 as well as inhibitors of SARS-

CoV-2 such as cyclic sulfonamide derivatives. 20

In this study, the core scaffold of 3-acyl-2-phenylamino-1,4-dihydroquinolin-4-(1H)-one of 54 our lead compound (1) 18 was changed to 2-amino-quinazolin-4(3H)-one (Figure 1) . Because 55 the aromatic rings substituted with halogen groups or electron withdrawing groups of 56 dihydroquinolinones 1 were important for activity, 2-amino-quinazolin-4(3H)-ones with aromatic rings fixed at the similar positions were designed and evaluated to find compound 2 58 as a hit (IC 50 = 2.6 μM for SARS-CoV-2). 2-Amino-quinazolin-4(3H)-one derivatives have 59 been known to possess high activities as inhibitors of aldose reductase, 21a K ATP channel opener, 60 21b anti-cancer agents, 21c and anti-hyperglycemic agents, 21d Here we report on the synthesis 61 and biological effects of 2-amino-quinazolin-4(3H)-one derivatives. and human and 11e is microsomally more unstable than 9g, which seems to be due to the 149 presence of -OH in the structure. In the cytotoxicity assay, 9g and 11e showed a little toxicity 150 in HFL-1 (CC 50 = 7.5 and 9.6 μM), but did not show toxicity in the rest of the cells ( In hERG channel inhibition assay, it was found that both compounds 9g and 11e did not 159 interact with hERG channel. In the PPB assay, both compounds 9g and 11e showed high The preliminary pharmacokinetic properties of 9g and 11e were investigated by intravenous 167 (i.v.) and oral (p.o) routes in rats, with 2 mg/kg and 10 mg/kg, respectively. The oral 168 bioavailability of 9g and 11e were 15.6% and 7.8%, respectively, partly because the clearance 169 of compound 11e is higher than that of 9g. The PK profile of 9g seemed to be acceptable for 170 the discovery of anti-coronavirus drugs. In conclusion, we designed and developed 2-aminoquinazolin-4(3H)-one derivatives as 

Severe Acute Respiratory Syndroms (SARS) 201 Overview

Middle East respiratory syndrome coronavirus 204 (MERS-CoV) situation update

Coronavirus Disease (COVID-19) Dashboard, 207 Global situation

World Health Organication (WHO) Director-General's opening remarks at the media 209 briefing on COVID-19